neffy, epinephrine nasal spray, Demonstrates a Positive Efficacy and Safety Profile for the Treatment of Allergic Reactions in Pediatric Patients at-Risk of Anaphylaxis: Phase 3 Study Results

被引：0

作者：

Ebisawa, Motohiro ^{[1
]}

Lowenthal, Richard ^{[2
]}

Tanimoto, Sarina ^{[3
]}

Takahashi, Kento ^{[4
]}

Takahashi, Kyohei Kyohei ^{[4
]}

Yanagida, Noriyuki ^{[4
]}

Sato, Sakura ^{[4
]}

机构：

[1] Sagamihara Natl Hosp, Sagamihara, Japan

[2] ARS Pharmaceut, San Diego, CA USA

[3] ARS Pharmaceut Inc, San Diego, CA USA

[4] NHO Sagamihara Natl Hosp, Sagamihara, Japan

来源：

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2024年 / 153卷 / 02期

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

L33

引用

页码：AB371 / AB371

页数：1

共 50 条

[1] Neffy, epinephrine nasal spray, demonstrates a positive efficacy and safety profile for the treatment of allergic reactions in pediatric patients at-risk of anaphylaxis
Ebisawa, Motohiro
Takahashi, Kyohei
Takahashi, Kento
Yanagida, Noriyuki
Sato, Sakura
Tanimoto, Sarina
CLINICAL AND EXPERIMENTAL ALLERGY, 2024, 54 (10): : 822 - 823
[2] Clinical efficacy and safety study of Loratadine combined with glucocorticoid nasal spray in the treatment of pediatric bronchial asthma with seasonal allergic rhinitis
Yang, Houjuan
Mao, Haiyu
Wang, Fei
Guo, Qing
Chu, Jiusheng
Zhao, Xiaojun
Lei, Dabang
JOURNAL OF ASTHMA, 2024, 61 (12) : 1698 - 1705
[3] Safety of Diazepam Nasal Spray in Pediatric Patients With Developmental Epileptic Encephalopathies: Results From a Long-term Phase 3 Safety Study
Tarquinio, Daniel
Wheless, James W.
Segal, Eric B.
Misra, Sunita N.
Rabinowicz, Adrian L.
Carrazana, Enrique
JOURNAL OF CHILD NEUROLOGY, 2023, : 389 - 393
[4] Safety and Effectiveness of Diazepam Nasal Spray With Concomitant Cannabidiol: Post Hoc Analysis of Pediatric Patients From a Phase 3 Safety Study
Peters, J.
Puri, V
Segal, E.
Misra, S.
Rabinowicz, A.
Carrazana, E.
ANNALS OF NEUROLOGY, 2023, 94 : S60 - S61
[5] Safety Profile of Valtoco® (diazepam nasal spray) in Patients With Epilepsy: Final Results From a Phase 3, Open-Label, 12-Month Repeat Dose Safety Study
Wheless, James
Sperling, Michael
Liow, Kore
Segal, Eric
Miller, Ian
Hogan, R. Edward
Tarquinio, Daniel
Desai, Jay
Dlugos, Dennis
Biton, Victor
Cascino, Gregory
Carrazana, Enrique
Rabinowicz, Adrian L.
NEUROLOGY, 2021, 96 (15)
[6] Efficacy and Safety of Zavegepant Nasal Spray for the Acute Treatment of Migraine: Results of a Phase 3 Double-Blind, Randomized, Placebo Controlled Trial
Mullin, K.
Croop, R.
Pavlovic, J.
Mosher, L.
Smith, T.
Madonia, J.
Lovegren, M.
Coric, V.
Lipton, R.
JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
[7] Efficacy and Safety of Zavegepant Nasal Spray for the Acute Treatment of Migraine: Results of a Phase 3 Double-Blind, Randomized, Placebo Controlled Trial
Mullin, Kathleen
Croop, Robert
Pavlovic, Jelena
Mosher, Linda
Smith, Timothy
Madonia, Jennifer
Lovegren, Meghan
Lipton, Richard
NEUROLOGY, 2023, 100 (17)
[8] Efficacy and Safety of Zavegepant Nasal Spray for the Acute Treatment of Migraine: Results of a Phase 3 Double-Blind, Randomized, Placebo Controlled Trial
Mullin, Kathleen
Croop, Robert
Pavlovic, Jelena M.
Mosher, Linda
Smith, Timothy R.
Madonia, Jennifer
Lovegren, Meghan
Coric, Vladimir
Lipton, Richard B.
CEPHALALGIA, 2022, 42 (1_SUPPL) : 126 - 127
[9] Efficacy and safety of zavegepant nasal spray for the acute treatment of migraine: Results of a phase 3 double-blind, randomized, placebo controlled trial
Mullin, K.
Croop, R.
Pavlovic, J. M.
Mosher, L.
Smith, T. R.
Madonia, J.
Lovegren, M.
Coric, V
Lipton, R. B.
HEADACHE, 2022, 62 : 128 - 129
[10] Study Design to Evaluate the Efficacy and Safety of Zolmitriptan Nasal Spray (ZNS) for the Acute Treatment of Migraine Headaches in Pediatric Patients Ages 6 to 11
Hershey, A. D.
Khanna, S.
Modi, N.
Gupta, S.
Wray, H.
Rubens, R.
HEADACHE, 2017, 57 : 195 - 195

← 1 2 3 4 5 →